Litigation

Recent Posts

GlaxoSmithKline To Settle 3 Federal Investigations For $3 Billion
Posted on 4 Nov 2011 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline plc (GSK) has reached an agreement in principal to settle three United States federal criminal and civil investigations for $3 billion, the company said Nov. 3 in a press release on its Web site. GSK said... Read More

Texas Risperdal Trial Ends When Janssen Settles For $158 Million, Company Says
Posted on 19 Jan 2012 by Tom Moylan

AUSTIN, Texas -- Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal... Read More

Jury Orders Warrick To Pay State $4.5M For Inflated Albuterol Prices
Posted on 1 Oct 2010 by Tom Moylan

BOSTON - (Mealey's) A Massachusetts federal jury on Oct. 1 ordered a defunct Merck & Co. Inc. subsidiary, Warrick Pharmaceuticals Corp., to pay $4,563,328 for causing the state to pay inflated prices for the asthma drug albuterol ( Commonwealth... Read More

Alabama High Court Vacates $78.4 Million Drug-Pricing Verdict Against Generic Maker Sandoz
Posted on 16 Jul 2012 by Tom Moylan

MONTGOMERY, Ala. - (Mealey's) In a 7-1 vote, the Alabama Supreme Court on July 13 vacated a $78.4 million drug-pricing verdict against generic drug maker Sandoz Inc., finding that the state government knew that the reported drug prices were not accurate... Read More

2 Drug Makers To Pay $214.5 Million For Off-Label Marketing Of Zonegran
Posted on 16 Dec 2010 by Tom Moylan

BOSTON - (Mealey's) Drug maker Elan Corp. PLC on Dec. 15 pleaded guilty to misdemeanor branding for the off-label marketing of the epilepsy drug Zonegran and will pay more than $203.5 million in criminal and civil penalties ( United States of America... Read More

Potential Pitfalls Involving Medicare Set-Asides, Special Needs Trusts
Posted on 10 Mar 2011 by Jennifer Jordan

By Jennifer C. Jordan, Esq., General Counsel, MEDVAL LLC Now that those involved in personal injury settlements, whether workers' compensation or liability insurance based, have finally come to understand the Medicare Secondary Payer Act ("MSP"... Read More

States Petition Supreme Court In Health Care Act Case
Posted on 29 Sep 2011 by Cheryl Keely

WASHINGTON, D.C. - (Mealey's) States challenging the Patient Protection and Affordable Care Act (PPACA) filed a petition on Sept. 28 for writ of certiorari with the U.S. Supreme Court, saying an 11th Circuit U.S. Court of Appeals decision affirming... Read More

Pa. High Court: Drug Company Lacks Standing To Challenge State’s Outside Counsel
Posted on 18 Aug 2010 by Tom Moylan

PHILADELPHIA - (Mealey's) Janssen Pharmaceutica Inc. lacks standing under Pennsylvania law to challenge the hiring of outside counsel to represent the state in a Risperdal off-label marketing lawsuit, the Pennsylvania Supreme Court ruled Aug. 17 ... Read More

Foley & Lardner LLP: 8th Circuit Dismisses Whistleblower's Suit Finding Facts Were Already Publicly Disclosed
Posted on 19 Aug 2014 by Foley & Lardner LLP

By Jacqueline N. Acosta In an August 7, 2014 opinion, the Eighth Circuit upheld the dismissal of a whistleblower’s suit alleging that a number of pain pump device makers had violated the False Claims Act (FCA) by marketing their pain pumps for... Read More

Williams Mullen: 4th Circuit Upholds Lengthy 'Stent' for Interventional Cardiologist
Posted on 10 Jul 2013 by Williams Mullen

By John Staige Davis V Can a cardiologist be sent to prison for performing medically unnecessary stent procedures, even though he stented a considerably lower percentage of his patients than his peers? In United States v. McLean, No. 11-5130 (Apr... Read More

Boehringer Ingelheim Pays $95 Million To Settle Off-Label, Kickback Claims In Civil Suit
Posted on 27 Oct 2012 by Tom Moylan

BALTIMORE — Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to the federal government to resolve civil allegations that it marketed three drugs for off-label uses, promoted high doses of two drugs and paid kickbacks to health care... Read More